definiens: means each of the following indications for a Gen e Therapy Product : ( a ) ALS through parvovirus vector delivery of nucleic acid polymers that silence nucleic acid or protein polymers enco ded by the C9ORF72 gene, ( b ) Krabbe disease ( globoid cell leukodystrophy ) through parvovirus vector delivery of nucleic acid polymers for expression of galactosylceramidase . ( c ) MLD through parvovirus vector delivery of nucleic acid polymers for expres sion of arylsulfatase A, ( d ) GLB1 Deficiency, for G M1 ganglios idosis- 1 and MPS IV through parvovirus vector delivery of nucleic acid polymers for expression of GLB1, ( e ) Frontotemporal dementia ( FTD ) through parvovirus vector delivery of nucleic acid polymers for expression of progranulin, ( f ) CMT2A t hrough parvoviru s vector delivery of nucleic acid polymers that silence nucleic acid or protein polym ers encoded by the MFN2 gene, and ( g ) parvovirus vector delivery of nucleic acid polymers for a spec ific named gene replacement transgene for a specifi c disease indication with treatment targeted to a spe cific locus ( ) added to the Agreement through exercise of a New Indication Option ( collec tively, the )